Relmada Therapeutics Inc
RLMD (NASDAQ)
Relmada Therapeutics Inc (RLMD) has emerged as a standout in the small-cap sector, boasting a remarkable one-year return of 1731.37%. Analysts are cautiously optimistic, setting a median 12-month price target of $8.50, with a range between $8.00 and $9.00, amid volatility that remains higher than 75% of U.S. stocks. While the five-year performance shows a decline of 30.92%, its recent upgrades from firms like Leerink Partners suggest potential for future growth.
Pros:
- Strong one-year performance
- Focus on CNS diseases
Cons:
- Negative five-year return
- C- rating from analysts
Relmada Therapeutics Inc (RLMD) may be suitable for investors with a high-risk tolerance who are looking for opportunities in the biotechnology sector, particularly those interested in speculative growth potential given its recent impressive one-year performance. However, the significant volatility and the decline over the past five years should prompt caution, making this investment more appropriate for those who can withstand market fluctuations and are willing to engage in long-term strategies.